ArticleCureus2026
Salvage Resection Following Reassessment of Resectability in Advanced Hepatocellular Carcinoma.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) management is commonly guided by the Barcelona Clinic Liver Cancer (BCLC) staging system; however, surgical resectability cannot always be accurately defined by staging alone. We report a case highlighting how initial misclassification of resectability led to loss of an early curative opportunity, while subsequent expert reassessment enabled successful salvage surgery. A 67-year-old man with chronic hepatitis B virus (HBV) infection was diagnosed with a large solitary HCC confined to the right hepatic lobe. Liver function was preserved, and there was no radiological evidence of vascular invasion or extrahepatic disease at presentation. Despite these favorable features, upfront surgical resection was not pursued. The patient underwent right portal vein embolization (PVE), which resulted in adequate hypertrophy of the future liver remnant, confirming technical resectability. Nevertheless, surgery was deferred, and transarterial radioembolization (TARE) was performed. During this interval, tumor progression occurred, with the development of a tumor thrombus in the right hepatic vein extending into the inferior vena cava (IVC), meeting criteria for advanced-stage disease. Following referral to a specialized hepatobiliary center, multidisciplinary reassessment determined that curative surgery remained feasible despite macrovascular involvement. The patient underwent right hepatectomy with resection of the right hepatic vein and inferior vena cava thrombectomy. Complete tumor removal with negative margins was achieved. The postoperative course was uneventful, and follow-up imaging at six months demonstrated no evidence of recurrence. This case illustrates the limitations of rigid guideline-based decision-making in HCC and underscores the importance of individualized surgical evaluation in experienced hepatobiliary centers. Continuous reassessment of resectability, particularly after locoregional therapies, may reveal curative options even in patients classified as having advanced disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.